Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Group [Editor's Choice]

Jul 1, 2020, 00:00 AM
10.1016/j.jval.2019.11.009
https://www.valueinhealthjournal.com/article/S1098-3015(20)30091-7/fulltext
Section Title : THEMED SECTION: APPLICATIONS OF HEALTH PREFERENCES RESEARCH
Section Order : 831
First Page : 831

Objective

This study examines European decision makers' consideration and use of quantitative preference data.

Methods

The study reviewed quantitative preference data usage in 31 European countries to support marketing authorization, reimbursement, or pricing decisions. Use was defined as: agency guidance on preference data use, sponsor submission of preference data, or decision-maker collection of preference data. The data could be collected from any stakeholder using any method that generated quantitative estimates of preferences. Data were collected through: (1) documentary evidence identified through a literature and regulatory websites review, and via key opinion leader outreach; and (2) a survey of staff working for agencies that support or make healthcare technology decisions.

Results

Preference data utilization was identified in 22 countries and at a European level. The most prevalent use (19 countries) was citizen preferences, collected using time-trade off or standard gamble methods to inform health state utility estimation. Preference data was also used to: (1) value other impact on patients, (2) incorporate non-health factors into reimbursement decisions, and (3) estimate opportunity cost. Pilot projects were identified (6 countries and at a European level), with a focus on multi-criteria decision analysis methods and choice-based methods to elicit patient preferences.

Conclusion

While quantitative preference data support reimbursement and pricing decisions in most European countries, there was no utilization evidence in European-level marketing authorization decisions. While there are commonalities, a diversity of usage was identified between jurisdictions. Pilots suggest the potential for greater use of preference data, and for alignment between decision makers.

https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)30091-7&doi=10.1016/j.jval.2019.11.009
HEOR Topics :
Tags :
  • benefit-risk assessment
  • European regulatory
  • health preferences
  • health technology assessment
  • marketing authorization
  • preference research
  • pricing
  • quantitative preference data
  • reimbursement
  • stakeholder preferences
Regions :